MX2019004863A - Anticuerpos anti-il-33 y usos de los mismos. - Google Patents
Anticuerpos anti-il-33 y usos de los mismos.Info
- Publication number
- MX2019004863A MX2019004863A MX2019004863A MX2019004863A MX2019004863A MX 2019004863 A MX2019004863 A MX 2019004863A MX 2019004863 A MX2019004863 A MX 2019004863A MX 2019004863 A MX2019004863 A MX 2019004863A MX 2019004863 A MX2019004863 A MX 2019004863A
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- treatment
- bind
- agents
- useful
- Prior art date
Links
- 206010012438 Dermatitis atopic Diseases 0.000 abstract 1
- 101000998137 Homo sapiens Interleukin-33 Proteins 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 201000008937 atopic dermatitis Diseases 0.000 abstract 1
- 102000045906 human IL33 Human genes 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente invención proporciona anticuerpos que se unen a IL-33 humana y la neutralizan, y métodos para usar los mismos, tales anticuerpos son útiles como agentes para el tratamiento de condiciones asociadas con enfermedad alérgica que incluye el tratamiento de dermatitis atópica.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662414258P | 2016-10-28 | 2016-10-28 | |
| PCT/US2017/058020 WO2018081075A1 (en) | 2016-10-28 | 2017-10-24 | Anti-il-33 antibodies and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019004863A true MX2019004863A (es) | 2019-08-12 |
| MX394799B MX394799B (es) | 2025-03-24 |
Family
ID=60263117
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019004863A MX394799B (es) | 2016-10-28 | 2017-10-24 | Anticuerpos anti-il-33 y usos de los mismos. |
Country Status (37)
| Country | Link |
|---|---|
| US (2) | US10501536B2 (es) |
| EP (1) | EP3532499B1 (es) |
| JP (1) | JP6830533B2 (es) |
| KR (1) | KR102266144B1 (es) |
| CN (1) | CN109863173B (es) |
| AR (1) | AR109948A1 (es) |
| AU (1) | AU2017351183B2 (es) |
| BR (1) | BR112019005139A2 (es) |
| CA (1) | CA3039232C (es) |
| CL (1) | CL2019001043A1 (es) |
| CO (1) | CO2019003047A2 (es) |
| CR (1) | CR20190179A (es) |
| CY (1) | CY1124360T1 (es) |
| DK (1) | DK3532499T3 (es) |
| EA (1) | EA201990778A1 (es) |
| EC (1) | ECSP19029758A (es) |
| ES (1) | ES2878037T3 (es) |
| HR (1) | HRP20211221T1 (es) |
| HU (1) | HUE055621T2 (es) |
| IL (1) | IL265689B2 (es) |
| JO (1) | JOP20190093A1 (es) |
| LT (1) | LT3532499T (es) |
| MA (1) | MA46619B1 (es) |
| MD (1) | MD3532499T2 (es) |
| MX (1) | MX394799B (es) |
| PE (1) | PE20191045A1 (es) |
| PH (1) | PH12019500929A1 (es) |
| PL (1) | PL3532499T3 (es) |
| PT (1) | PT3532499T (es) |
| RS (1) | RS62120B1 (es) |
| SI (1) | SI3532499T1 (es) |
| SM (1) | SMT202100442T1 (es) |
| TN (1) | TN2019000086A1 (es) |
| TW (2) | TWI676680B (es) |
| UA (1) | UA121293C2 (es) |
| WO (1) | WO2018081075A1 (es) |
| ZA (1) | ZA201901935B (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190093A1 (ar) * | 2016-10-28 | 2019-04-25 | Lilly Co Eli | أجسام مضادة لـ il-33 واستخداماتها |
| AU2020368369A1 (en) | 2019-10-15 | 2022-05-12 | Eli Lilly And Company | Recombinantly engineered, lipase/esterase-deficient mammalian cell lines |
| KR20220093334A (ko) | 2019-11-04 | 2022-07-05 | 메디뮨 리미티드 | Il-33 길항제의 이용 방법 |
| CA3158366A1 (en) | 2019-11-04 | 2021-05-14 | Medimmune Limited | Anti il-33 therapeutic agent fpr treating renal disorders |
| CN113214395A (zh) * | 2020-01-21 | 2021-08-06 | 迈威(上海)生物科技股份有限公司 | 抗st2抗体及其应用 |
| EP4118114A1 (en) | 2020-03-13 | 2023-01-18 | Genentech, Inc. | Anti-interleukin-33 antibodies and uses thereof |
| WO2021180858A1 (en) | 2020-03-13 | 2021-09-16 | Medimmune Limited | Therapeutic methods for the treatment of subjects with risk alelles in il33 |
| AU2021253117B2 (en) | 2020-04-06 | 2025-08-14 | Medimmune Limited | Treating acute respiratory distress syndrome with IL-33 axis binding antagonists |
| EP4149521A1 (en) | 2020-05-11 | 2023-03-22 | MedImmune Limited | Formulations of anti-il-33 antibodies |
| CN111620948B (zh) * | 2020-06-10 | 2022-04-08 | 南京赛新生物科技有限公司 | 针对il-33的抗体 |
| CN113603775B (zh) * | 2021-09-03 | 2022-05-20 | 江苏荃信生物医药股份有限公司 | 抗人白介素-33单克隆抗体及其应用 |
| TW202402790A (zh) | 2022-03-25 | 2024-01-16 | 英商梅迪繆思有限公司 | 減少呼吸系統感染之方法 |
| WO2024038185A1 (en) | 2022-08-19 | 2024-02-22 | Medimmune Limited | Method of selecting patients for treatment with an il-33 axis antagonist |
| WO2025114862A1 (en) * | 2023-11-27 | 2025-06-05 | Glaxosmithkline Intellectual Property Development Limited | Il-33 binding antibodies |
| WO2025120567A1 (en) | 2023-12-07 | 2025-06-12 | Medimmune Limited | Method of treatment of asthma |
| WO2025210099A1 (en) | 2024-04-04 | 2025-10-09 | Medimmune Limited | Method of treatment and selecting a subject |
| WO2025242618A1 (en) | 2024-05-20 | 2025-11-27 | Medimmune Limited | Bronchiectasis treatment |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ549040A (en) | 2004-02-17 | 2009-07-31 | Schering Corp | Use for interleukin-33 (IL33) and the IL-33 receptor complex |
| EP2152740A1 (en) | 2007-04-26 | 2010-02-17 | Provost, Fellows and Scholars of the College of the Holy and Undivided Trinity of Queen Elizabeth near Dublin | Products for altering il-33 activity and methods therefor |
| US20100260770A1 (en) | 2007-05-18 | 2010-10-14 | Medimmune, Llc | Il-33 in inflammatory disease |
| WO2011031600A1 (en) * | 2009-09-10 | 2011-03-17 | Schering Corporation | Use of il-33 antagonists to treat fibrotic disease |
| KR102003075B1 (ko) * | 2011-02-23 | 2019-07-23 | 에프. 호프만-라 로슈 아게 | 인간 il33r에 대한 항체 및 이의 용도 |
| FR2972006B1 (fr) | 2011-02-24 | 2016-03-25 | Centre Nat Rech Scient | Nouveaux fragments d'il-33 superactifs et leurs utilisations |
| US9090694B2 (en) | 2012-04-30 | 2015-07-28 | Janssen Biotech, Inc. | ST2L antibody antagonists |
| JO3532B1 (ar) * | 2013-03-13 | 2020-07-05 | Regeneron Pharma | الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها |
| US9758578B2 (en) * | 2013-12-26 | 2017-09-12 | Mitsubishi Tanabe Pharma Corporation | Human anti-IL-33 neutralizing monoclonal antibody |
| AU2015204674B2 (en) * | 2014-01-10 | 2020-09-03 | Anaptysbio, Inc. | Antibodies directed against interleukin-33 (IL-33) |
| WO2015164354A1 (en) * | 2014-04-21 | 2015-10-29 | The Childen's Hospital Of Philadelphia | Compositions and methods for treating cytokine-related disorders |
| US10093730B2 (en) | 2014-11-10 | 2018-10-09 | Genentech, Inc. | Anti-interleukin-33 antibodies and uses thereof |
| CA2982400C (en) | 2015-03-31 | 2023-10-24 | Medimmune Limited | A novel il33 form, mutated forms of il33, antibodies, assays and methods of using the same |
| AU2017208099A1 (en) | 2016-01-14 | 2018-08-09 | Anaptysbio, Inc. | Inhibition of allergic reaction using an IL-33 inhibitor |
| JOP20190093A1 (ar) * | 2016-10-28 | 2019-04-25 | Lilly Co Eli | أجسام مضادة لـ il-33 واستخداماتها |
-
2017
- 2017-06-16 JO JOP/2019/0093A patent/JOP20190093A1/ar unknown
- 2017-10-13 TW TW107143762A patent/TWI676680B/zh active
- 2017-10-13 AR ARP170102863A patent/AR109948A1/es unknown
- 2017-10-13 TW TW106135006A patent/TWI647238B/zh active
- 2017-10-24 WO PCT/US2017/058020 patent/WO2018081075A1/en not_active Ceased
- 2017-10-24 EP EP17794593.8A patent/EP3532499B1/en active Active
- 2017-10-24 PL PL17794593T patent/PL3532499T3/pl unknown
- 2017-10-24 BR BR112019005139A patent/BR112019005139A2/pt unknown
- 2017-10-24 PT PT177945938T patent/PT3532499T/pt unknown
- 2017-10-24 DK DK17794593.8T patent/DK3532499T3/da active
- 2017-10-24 RS RS20210875A patent/RS62120B1/sr unknown
- 2017-10-24 CR CR20190179A patent/CR20190179A/es unknown
- 2017-10-24 SM SM20210442T patent/SMT202100442T1/it unknown
- 2017-10-24 MD MDE20190980T patent/MD3532499T2/ro unknown
- 2017-10-24 CN CN201780065572.XA patent/CN109863173B/zh active Active
- 2017-10-24 TN TNP/2019/000086A patent/TN2019000086A1/en unknown
- 2017-10-24 HR HRP20211221TT patent/HRP20211221T1/hr unknown
- 2017-10-24 US US15/791,641 patent/US10501536B2/en active Active
- 2017-10-24 PE PE2019000838A patent/PE20191045A1/es unknown
- 2017-10-24 UA UAA201903400A patent/UA121293C2/uk unknown
- 2017-10-24 ES ES17794593T patent/ES2878037T3/es active Active
- 2017-10-24 MA MA46619A patent/MA46619B1/fr unknown
- 2017-10-24 KR KR1020197012190A patent/KR102266144B1/ko active Active
- 2017-10-24 HU HUE17794593A patent/HUE055621T2/hu unknown
- 2017-10-24 AU AU2017351183A patent/AU2017351183B2/en active Active
- 2017-10-24 EA EA201990778A patent/EA201990778A1/ru unknown
- 2017-10-24 MX MX2019004863A patent/MX394799B/es unknown
- 2017-10-24 CA CA3039232A patent/CA3039232C/en active Active
- 2017-10-24 LT LTEP17794593.8T patent/LT3532499T/lt unknown
- 2017-10-24 IL IL265689A patent/IL265689B2/en unknown
- 2017-10-24 JP JP2019522272A patent/JP6830533B2/ja active Active
- 2017-10-24 SI SI201730830T patent/SI3532499T1/sl unknown
-
2019
- 2019-03-28 CO CONC2019/0003047A patent/CO2019003047A2/es unknown
- 2019-03-28 ZA ZA201901935A patent/ZA201901935B/en unknown
- 2019-04-16 CL CL2019001043A patent/CL2019001043A1/es unknown
- 2019-04-25 PH PH12019500929A patent/PH12019500929A1/en unknown
- 2019-04-26 EC ECSENADI201929758A patent/ECSP19029758A/es unknown
- 2019-10-25 US US16/663,561 patent/US10913793B2/en active Active
-
2021
- 2021-07-26 CY CY20211100672T patent/CY1124360T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019004863A (es) | Anticuerpos anti-il-33 y usos de los mismos. | |
| CR20230477A (es) | MOLÉCULAS DE ANTICUERPO QUE SE UNEN A CD73 Y USOS DE LAS MISMAS (Divisional Exp. 2019-0593) | |
| CY1126255T1 (el) | Χρησεις ανταγωνιστων il-13 για την αγωγη της ατοπικης δερματιτιδας | |
| CL2018001512A1 (es) | Anticuerpos anti-cd73 humanizados. | |
| CO2018001485A2 (es) | Diacuerpos monovalentes biespecificos que son capaces de unirse a b7 - h3 y cd3 | |
| MX2015010599A (es) | Anticuerpos dirigidos contra il-33 y sus usos. | |
| CO2017005240A2 (es) | Inmunoglobulinas hetero-diméricas de redireccionamiento de células t cd3/cd38 y sus métodos de producción | |
| CO2017005784A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
| MX370506B (es) | Método para tratar trastorno de estrés post-traumático. | |
| EA201790984A1 (ru) | Анти-cd79b антитела и способы их применения | |
| CO2017007121A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
| NI201800134A (es) | Anticuerpos antifactor de la coagulación xi | |
| CL2018002340A1 (es) | Anticuerpos para il-17c | |
| CO2019012756A2 (es) | Anticuerpos agonistas contra btla y sus usos | |
| CO2018008249A2 (es) | Composiciones terapéuticas y métodos para el tratamiento de la hepatitis b | |
| AR101486A1 (es) | Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso | |
| MX2015010728A (es) | Metodos y composiciones para el tratamiento de leucemia. | |
| EP3564265A4 (en) | Trifunctional molecule and application thereof | |
| AR101671A1 (es) | Anticuerpos anti proteína similar a angiopoyetina-4 (angptl4) y métodos de uso | |
| CL2020000920A1 (es) | Anticuerpo monoclonal anti-il-5ra. | |
| CO2017010621A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
| BR112017025264A2 (pt) | tratamento de prurido | |
| CO2018007236A2 (es) | Reguladores cftr y métodos de uso | |
| DOP2019000082A (es) | Anticuerpos anti-il-33 y usos de los mismos | |
| AR129996A2 (es) | Anticuerpos dirigidos contra il-33 y sus usos |